Voiding Dysfunction/BPH
.jpg "Eric Rovner, MD photo")
Eric Rovner, MD
MD
Medical University of South Carolina
Christopher Chapple, MD,FEBU,FRCS,MBBS,BS
Consultant Urological Surgeon
Sheffield Teaching Hospitals NHS Foundation Trust, University of Sheffield, Sheffield Hallam University
Alan Wein, MD, PhD(hon) (he/him/his)
Professor with Tenure and Emeritus Chief of Urology and Associate Director, Resi
University of Pennsylvania
Course Description: Much has been written and debated about drug treatment of overactive bladder (OAB) over the past two decades. Nevertheless, the field continues to evolve. OAB pharmacotherapy remains an area of active investigation and innovation. The publication of the recently updated AUA/Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction Guideline titled “Diagnosis and Treatment of Overactive Bladder (Non-neurogenic) in Adults,” the proceedings of the 7th International Consultation on Incontinence, as well as European Association of Urology Guidelines have maintained considerable interest in this area among researchers and practitioners. This course will describe the physiological and pharmacological underpinnings of modern drug treatment of OAB, review currently available agents and discuss agents in development.